NCT04460456 2022-06-30A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsSilverback TherapeuticsPhase 1 Unknown58 enrolled
NCT02675946 2022-01-26CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Curegenix Inc.Phase 1 Unknown72 enrolled